G6PD and renal cell carcinoma: In animal studies, CAF administration has been shown to inhibit tumor growth partly via disruption of tumor redox homeostasis; for instance, a recent study found CAF targets glucose-6-phosphate dehydrogenase (G6PD) in renal cell carcinoma cells, impairing the pentose phosphate pathway and tipping the redox balance toward oxidative stress to inhibit tumor growth [21].